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Strategies for national health care systems in emerging coun-
tries: The case of screening and prevention of renal disease
progression in Bolivia. There are close to 1 million people in
the world who are alive simply because they have access to one
form or another of renal replacement therapy (RRT). Ninety
percent live in high-income countries. Little is known of preva-
lence and incidence of chronic kidney disease and of end-stage
renal disease (ESRD) in middle-income and low-income coun-
tries, where the use of RRT is scarce or nonexistent. However,
no intervention is undertaken, these people will experience
progression to ESRD and death from uremia, because RRT
is out of reach for them. These are the individuals for whom ef-
forts should be focused to prevent or delay progression toward
ESRD.
In 1992, the Mario Negri Institute for Pharmacological Re-
search in Bergamo, Italy, with the cooperation of the young
doctors of the Ospedale Giovanni XXIII in La Paz (Bolivia),
activated a specific project titled “El Proyecto de Enfermedades
Renales en Bolivia” (The Project for Renal Diseases in Bolivia).
The project sought to demonstrate that in emerging countries
the best strategies against renal disease are prevention and early
detection. After proper training of local personnel at the Clini-
cal Research Center “Aldo e Cele Dacco” of the Mario Negri In-
stitute in Bergamo, Italy, an educational campaign titled “First
Clinical and Epidemiological Program of Renal Diseases”—
under the auspices of the Renal Sister Center Program of the
International Society of Nephrology—was conducted in 3 se-
lected areas of Bolivia, including tropical, valley, and plains ar-
eas. The goal was to define the frequency of asymptomatic renal
disease in these areas by screening a large population of patients
at relatively low costs. The screening was formally performed at
first-level health centers (Unidad de Salud). Participants were
instructed to void a clean urine specimen, and a dipstick test
was performed. Patients with positive urinalysis were enrolled
in a follow-up program with subsequent laboratory and clinical
checks. The study was conducted by 21 clinical centers. Appar-
ently healthy patients (14,082) were enrolled over a period of 7
months. Urinary abnormalities were found on first screening in
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4261 patients, but only 1019 patients (23.9%) were available for
follow-up. At second urinalysis, 35% of patients had no abnor-
malities. In the remaining positive group of patients, further in-
vestigations disclosed the following abnormalities: urinary tract
infection (48.4%), isolated hematuria (43.9%), chronic renal
failure (1.6%), renal tuberculosis (1.6%), and other diagnoses
4.3% (kidney stones, 1.3%; diabetic nephropathy, 1%; polycys-
tic kidney diseases, 1.9%).
The experience gained from this initial screening program
formed the basis for a second study aimed to prevent renal
disease progression in a selected Bolivian population with high
altitude polycythemia.
In conclusion, our studies show that mass screening of the
population for renal disease is feasible in developing countries
and can provide useful information on frequency of renal dis-
eases. Also, in patients with altitude polycythemia, long-term
treatment with low doses of enalapril safely prevents increase
in arterial blood pressure and progressively reduces hematocrit
and proteinuria. Aside from its scientific value, this last study
can be taken as an example of how, by rationalizing resources
and investing in research programs, renal disease progression
and cardiovascular risk may eventually improve, which ulti-
mately should translate into less demand for dialysis, and thus
provide alternatives to costly RRT. The transformation of the
Bolivian pilot model into a systematic program applicable to
most emerging countries may be seen as a task of national
nephrology societies, along with methodologic and economic
support of international bodies.
Resumen
Existen cerca de 1 millo´n de personas en el mundo que viven
gracias a que tienen acceso a una forma u otra de terapia de
reemplazo de la funcio´n renal (1). El 90% de ellas viven en
paı´ses desarrollados, donde el ingreso promedio per ca´pita es
mayor de $10,000.00 do´lares americanos (2). Poco se sabe so-
bre la prevalencia de IRC en paı´ses en desarrollo, donde el uso
de la dia´lisis es limitado o inexistente. En Ame´rica Latina se
reporta una prevalencia de 300 pacientes por millo´n de habi-
tantes (pmh), comparada con cerca de 1,100 pmh en los Estados
Unidos de Ame´rica, 1,400 en Japo´n y 650 pmh en Europa Oc-
cidental. La incidencia anual de IRC reportada en esta regio´n
varı´a de 34 pmh en Bolivia a 300 pmh en Brasil, en una clara
relacio´n a la riqueza del paı´s. A pesar de no existir informacio´n
sobre la prevalencia de enfermedad renal anterior a la dia´lisis
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en paı´ses en desarrollo, es razonable suponer que las cifras sean
similares a las observadas en paı´ses desarrollados. Si no se in-
terviene oportunamente, estos pacientes evolucionara´n hacia la
IRC, uremia y muerte, ya que la dia´lisis esta´ fuera de su alcance.
Estos son los pacientes en quienes creemos se deben dirigir los
esfuerzos para prevenir y retardar el dan˜o renal.
En 1992 el Instituto de Investigacio´n Farmacolo´gica Mario
Negri de Bergamo, Italia, a nombre del proyecto general Mario
Negri para Ame´rica Latina y con el apoyo de la Associazione
il Conventito y la cooperacio´n de los me´dicos del Hospital
Juan XXIII de la Paz, Bolivia, iniciaron el “Proyecto de Enfer-
medades Renales en Bolivia. El objetivo fue el demostrar que
la mejor estrategia para tratar la enfermedad renal en paı´ses
en desarrollo, es a trave´s su prevencio´n y deteccio´n temprana.
Despue´s de capacitar al personal local en el Centro de Investi-
gacio´n Clı´nica “Aldo y Cele Dacco” del Instituto Mario Negri,
se inicio´ una campan˜a educacional titulada “Primer Programa
Clı´nico y Epidemiolo´gico de las Enfermedades Renales,” bajo
el auspicio del programa Centros Renales Hermanos de la So-
ciedad Internacional de Nefrologı´a, en tres a´reas seleccionadas
en Bolivia, que incluyeron las regiones tropical, el valle y los
planos del paı´s. El objetivo fue identificar la frecuencia de
enfermedad renal asintoma´tica, a trave´s de evaluar al mayor
nu´mero de habitantes a un bajo costo. La evaluacio´n se realizo´
en el primer nivel de salud (Unidad de Salud). Se recolectaron
muestras de orina y se practico´ una prueba con cinta reactiva.
Posteriormente, la muestras se centrifugaron y el sedimento se
resuspendio´ para examen microsco´pico. Aquellas personas con
un examen positivo tuvieron un seguimiento posterior, que in-
cluyo´ un uriana´lisis completo, quı´mica sanguı´nea, urocultivo y
de ser necesario, ultrasonido renal y pielograma excretor. El
estudio se llevo´ a cabo en 21 Unidades de Salud y se evaluaron
14,082 personas en un periodo de 7 meses. La edad prome-
dio fue de 20.2 an˜os; 6,759 (48%) fueron del sexo masculino y
7,323 (52%) del sexo femenino. Se detectaron anormalidades
urinarias en el primer examen en 4,261 (30%) personas. De es-
tos, solo 1,019 (23.9%) acudieron a una evaluacio´n posterior.
En el segundo examen de orina, 35% no presentaron ninguna
anormalidad. En la evaluacio´n posterior de los casos positivos
se encontro´ infeccio´n de tracto urinario en 48.4%, hematuria
aislada en 43.9%, insuficiencia renal cro´nica en 1.6%) y otras
patologı´as en 4.3% (litiasis renal 1.3%, neuropatı´a diabe´tica 1%
y rin˜o´n poliquı´stico en 1.9%) de los casos.
La experiencia ganada en este estudio, sento´ las bases para
un segundo proyecto dirigido a la prevencio´n de la enfermedad
renal en un grupo selecto de la poblacio´n boliviana. Debido a
que Bolivia se encuentra a una gran altitud sobre el nivel del
mar, el objetivo fue el demostrar que la policitemia asociada a
la altitud es un factor de riesgo para desarrollar proteinuria; la
intervencio´n farmacolo´gica con un inhibidor de la enzima con-
vertidora de la angiotensina puede controlar e´sta y disminuir la
excrecio´n urinaria de proteı´na, contribuyendo ası´ a retardar la
progresio´n del dan˜o renal. El estudio fue prospectivo, abierto
y aleatorio e incluyo´ a 26 personas mestizas, que nacieron en
localidades ubicadas entre los 3,200 m y 4000 m sobre el nivel
del mar (snm) y que habı´an residido en La Paz (3,600 m snm)
cuando menos durante 1 an˜o. Policitemia se definio´ como un
hematocrito ≥ 55% y proteinuria como una excrecio´n urinaria
de proteina ≥ 150 mg/24 h, medidos en dos ocasiones, separados
por dos meses. Personas con una presio´n arterial diasto´lica > 90
mmHg, diabetes, insuficiencia pulmonar o cardiaca, policitemia
vera, insuficiencia renal (creatinina se´rica > 1.4,g/dL) o un ul-
trasonido sugestivo de enfermedad renal, fueron excluidos del
estudio. Trece sujetos recibieron enalapril (5 mg/dı´a) por 2 an˜os
(grupo de estudio) y 13 no recibieron tratamiento alguno (grupo
control). En todos lo participantes el hematocrito basal se rela-
ciono´ en forma significativa con el peso corporal (r = 0.46, P =
0.02), presio´n arterial sisto´lica (r = 0.49, P < 0.01) y diasto´lica
(r = 0.40, P < 0.04) y muy significativamente con la creatinina
se´rica (r = 0.61, P < 0.0009) y la excrecio´n urinaria de pro-
teina (r = 0.56, P < 0.003). El hematocrito, la concentracio´n de
hemoglobina y la proteinuria disminuyeron significativamente
en el grupo de estudio; por el contrario, se incrementaron en
el grupo control. Las diferencias entre los dos grupos a los 12 y
24 meses de seguimiento fueron estadı´sticamente significantes
(P < 0.01). En el grupo de estudio, ma´s no ası´ en el de control,
los cambios en el hematocrito se correlacionaron positivamente
con cambios en la presio´n arterial sisto´lica y la excrecio´n uri-
naria de proteı´na. En el ana´lisis de regresio´n linear por paciente,
se encontro´ una correlacio´n positiva y altamente significante en-
tre los cambios del hematocrito y la proteinuria (r = 0.88, P <
0.0001) a los 6, 12, 18 y 24 meses en comparacio´n a las cifras
basales.
En conclusio´n, nuestros estudios muestran que la evalu-
acio´n masiva de la poblacio´n para detectar enfermedad renal
es posible en paı´ses en desarrollo y que puede proporcionar
informacio´n u´til sobre la prevalencia de enfermedad renal. Ası´
mismo, en personas con policitemia debido a la altura, el uso
de enalapril a dosis bajas por periodos prolongados, previene el
incremento de la presio´n arterial y reduce progresivamente el
hematocrito y la proteinuria. Independientemente de su valor
cientı´fico, este u´ltimo estudio muestra que racionalizando los re-
cursos econo´micos e invirtiendo en programas de investigacio´n,
el riesgo de progresio´n del dan˜o renal y de enfermedad car-
diovascular pueden reducirse, disminuyendo ası´ la demanda de
dia´lisis y ofreciendo alternativas a las terapias costosas de reem-
plazo de la funcio´n renal. La transformacio´n del modelo piloto
boliviano en un programa sistema´tico aplicado a otros naciones
emergentes, puede ser visto como una labor de la sociedades na-
cionales de nefrologı´a, con el apoyo econo´mico y metodolo´gico
de organismos internacionales.
THE BURDEN OF CHRONIC RENAL DISEASE
IN EMERGING COUNTRIES
There are about 1 million people in the world who are
alive simply because they have access to one form or an-
other of renal replacement therapy (RRT) [1]. Ninety
percent of them live in high-income countries, where the
average gross income is in excess of US $10,000 per capita
[2]. Over the last decade, the number of those requiring
dialysis has increased annually by 11% in Japan [3], 9%
in Australia [4], and 6.1% in Canada [5]. In the same pe-
riod, data from national and regional registries in West-
ern Europe have shown RRT rates increasing from 3% to
4.3% per year [6–9]. Much less is known about the preva-
lence and incidence of end-stage renal disease (ESRD) in
middle-income and low-income countries, where the use
of RRT is scarce or nonexistent. Overall, Latin America
has about 300 patients per million population (pmp) in
RRT compared with about 1100 pmp in the United States,
1400 pmp in Japan, and 650 pmp in Western Europe.
The reported annual incidence of patients with ESRD
in Latin America, however, varies widely, from as low
as 34 pmp in Bolivia to 300 pmp in Brazil, with a clear
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direct relationship with gross national product [10]. The
number of patients accepted by dialysis program is about
80 pmp in Egypt, 20 pmp in Malaysia, and even lower
in other countries [11, 12]. Less than 10% of all patients
with ESRD receive any kind of RRT in countries such
as India and Pakistan. In India, with an estimated inci-
dence of ESRD of 100 pmp, approximately 100,000 pa-
tients develop ESRD each year. Of these, 90% never see
a nephrologist. Of the 10,000 patients who do consult a
nephrologist, RRT is initiated in 90%; the remaining 10%
are unable to afford any form of RRT. Of the 8500 pa-
tients who start hemodialysis, 60% are lost to follow-up
within 3 months. These patients drop out of therapy, be-
cause they realize that dialysis is not a cure and has to be
performed over the long term, ultimately causing impov-
erishment of their families [13]. Although the incidence
of ESRD in China is estimated to be 5 pmp, in relatively
economically developed areas of this country, especially
in major cities, the incidence of ESRD is currently 102
pmp [14]. Central and Eastern Europe fall somewhere in
the middle between developed and emerging countries,
but the situation differs in individual parts of this region,
with the most severe being in the former Soviet Union,
Albania, and Romania [15].
Patients on RRT can be regarded as the tip of an ice-
berg, whereas the number of those with chronic kid-
ney disease (CKD) not yet in need of RRT is much
greater. However, the prevalence of predialysis CKD is
not known and only rough estimates exist. In the United
States, CKD affects approximately 11% of the adult pop-
ulation (20 million adults from 1988 to 1994). According
to the third National Health and Nutritional Examination
Survey, among the U.S. noninstitutionalized population,
10.9 million people are estimated to have creatinine val-
ues of 1.5 mg/dL or greater, 3.0 million have values of 1.7
mg/dL or greater, and 0.8 million have serum creatinine
levels of 2.0 mg/dL or greater [16].
Although no data are available concerning the preva-
lence of predialysis CKD in low-income countries, we
would expect that there are comparable numbers of pa-
tients with CKD in poor countries as in developed na-
tions. If no intervention is undertaken, these people will
experience progression to ESRD and death from uremia
because RRT is out of reach for them. These are the in-
dividuals on whom efforts should be focused to prevent
or delay progression toward ESRD. We believe that with
some effort, using a combination of pharmacologic and
nonpharmacologic approaches, prevention of the pro-
gression of renal disease is possible in less-developed
countries. Screening programs can be implemented with
simple, cheap, and reliable tests, such as measurement
of body weight, blood pressure, blood glucose, and dip-
stick urinalysis for protein. Examples already exist. In
India and Bolivia, a large number of people have been
screened already using affordable methods [17, 18]. Here,
we will analyze in more detail the case of screening and
prevention of renal disease in Bolivia.
A PROJECT FOR RENAL DISEASE IN BOLIVIA
In 1992, the Mario Negri Institute for Pharmacolog-
ical Research in Bergamo, Italy, on behalf of the gen-
eral project, Mario Negri for Latin America, through the
support of the Associazione il Conventino (Bergamo,
Italy), and with the cooperation of the young doctors
of the Ospedale Giovanni XXIII in La Paz (Bolivia),
activated a specific project titled “El Proyecto de En-
fermedades Renales en Bolivia” (The Project for Renal
Diseases in Bolivia). The project established an initia-
tive for Bolivia that was mainly directed at education
and prevention in the field of renal diseases, bearing in
mind that Bolivia is a developing country and that RRT,
like dialysis or transplantation, is only available for pa-
tients who earn over US $1500 monthly; however, most
people have a monthly salary of less than US $70. There-
fore, the project sought to demonstrate that in emerging
countries the best strategies against renal disease are pre-
vention and early detection. The general objective was to
give tools for advancement in nephrology in Bolivia that
would help identify patients at risk for developing re-
nal diseases later in life, with the hope of providing the
basis for building a regional and nationwide prevention
strategy, and in a second phase to activate a therapeutic
intervention program that would be extended to the en-
tire population. This would limit the need for dialysis and
transplantation. Prevention is more and more important
in this setting, given the shortage of financial resources
and the fact that dialysis centers, equipment, and trained
personnel are simply not available to the general popu-
lation.
The simplest and least expensive way of screening ap-
parently healthy patients is urinalysis, and several studies
have been made using reagent strips, which document
their effectiveness in detecting urinary abnormalities at
relatively low cost [19–23]. Urinalysis remains a corner-
stone in the evaluation of the kidney and may also be
easily used in mass screening for renal abnormalities in
a developing country [24–28]. We have considered this
screening program in Bolivia as a preliminary stage in an
articulated plan aimed at setting in motion a large-scale
preventive protocol to help reduce the number of patients
who will reach end-stage renal failure in Bolivia over the
next few years.
THE LARGE-SCALE CAMPAIGN OF PUBLIC
INFORMATION AND SCREENING OF RENAL
DISEASES
After proper training of local personnel at the Clini-
cal Research Center “Aldo e Cele Dacco” of the Mario
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La Paz
Rural area in highland
Beni
Bolivia
Cochabamba
Marginal urban areas
Rural areas
Marginal urban areas
Marginal urban areas
Fig. 1. Areas involved in the epidemiologic
program in Bolivia.
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(pediatr., gynecol.
internist, general)
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Fig. 2. Screening at first-level health centers.
Negri Institute in Bergamo, Italy, an educational cam-
paign titled “First Clinical and Epidemiological Pro-
gram of Renal Diseases”—under the auspices of the
Renal Sister Center Program of the International Soci-
ety of Nephrology—was conducted in 3 selected areas
of Bolivia, including the tropical, valley, and plains areas
(Fig. 1). The goal was to define the frequency of asymp-
tomatic renal disease in these areas by screening a
large population of patients at relatively low costs. The
campaign was conducted by doctors, nurses, and social
workers with the aid of brochures prepared for a largely il-
literate population. For this reason, an information leaflet
was distributed to 25,000 people; it explained the ba-
sic principles of kidney function and malfunction and
the aims of the screening program in very simple lan-
guage and with the aid of cartoons. The screening was
formally performed at first-level health centers (Unidad
de Salud) (Fig. 2). Participants were instructed to void a
clean urine specimen into a 200-mL vessel. A dipstick
test was performed on the unspun urine specimen by
trained laboratory technicians. The reagent strip is de-
signed to react progressively, producing color changes
after given intervals of time. The results were decided
by careful visual comparison of the test strip with a color
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Tropical region Valley region
25,000 brochures distributed
First screening
14,082 people
4261 positive
dipstick
Confirmatory test
Clinical work-up
1019 people
available for follow-up
Plains region
Fig. 3. Algorithm of educational and screen-
ing phases.
chart provided on the bottle label. The urine was then
prepared for microscopic analysis by centrifuging well-
mixed samples and examining a drop of the resuspended
sediment by subdued bright-field illumination under a
light microscope. Patients with positive urinalysis were
enrolled in a follow-up program with subsequent labo-
ratory and clinical checks. Complete urinalysis, biochem-
istry, and microbiology assays were performed during the
follow-up.
The study was conducted by 21 clinical centers dis-
tributed in 3 areas of the country, which represent 3
different geographic and socioeconomic environments.
Apparently healthy people (14,082) were enrolled over
a period of 7 months (Fig. 3). The mean age of the pop-
ulation was 20.2 years; there were 6759 (48%) men and
7323 (52%) women. Urinary abnormalities were found
at first screening in 4261 patients (Table 1). Patients were
then invited to come back for a confirmatory urinalysis,
if needed. Only 1019 patients (23.9% of the group with
a positive dipstick test) were available for the follow-up.
At second urinalysis, 35% of patients had no abnormal-
ities. In the remaining positive group of patients, further
investigations, including biochemistry, microbiology, ul-
trasound, and intravenous pyelography, were indicated.
The final diagnoses were as follows: urinary tract infec-
tion (48.4%), isolated hematuria (43.9%), chronic renal
failure (1.6%), renal tuberculosis (1.6%), and other diag-
noses 4.3% (kidney stones, 1.3%; diabetic nephropathy,
1%; polycystic kidney diseases, 1.9%).
This study shows that through an extended informa-
tion campaign, mass screening of the population for re-
nal ailments is feasible in a developing country and can
Table 1. Urinary findings at first screening
Number of % of screened
Urinary findings subjects population
Hematuria 2010 14.3
Leukocyturia 1765 12.5
Proteinuria 298 2.1
Proteinuria and glycosuria 37 0.3
Proteinuria and hematuria 15 0.1
provide useful information on the frequency of renal dis-
eases. However, the difficulties of such a large-scale study
emerged when we tried to test, for a second time, those
patients who had a positive dipstick at the first check.
Among the rural population, traditional medicine is still
quite widespread. The medicine man needs to visit the pa-
tient only once for diagnosis and treatment prescription.
It is not customary to go back again for the same prob-
lem. Moreover, we were looking for asymptomatic re-
nal abnormalities, and patients were not concerned about
following up with us. Therefore, only 24% of positive pa-
tients returned for a second check. Nevertheless, our re-
sults show that among apparently healthy patients in rural
and metropolitan areas of Bolivia, there is considerable
incidence of renal abnormalities, as reflected in the abnor-
mal dipstick findings. These findings underline the need
for educational campaigns and prevention programs for
renal diseases in emerging countries such as Bolivia.
THE DEVELOPMENT OF RESEARCH
PROGRAMS
The experience gained from this initial screening
program formed the basis for planning pilot studies to
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prevent renal disease progression in a selected target pop-
ulation in Bolivia [29]. This is in line with the mission
of the Research Committee of the Commission for the
Global Advancement of Nephrology of the International
Society of Nephrology that has been established with the
general aim of providing opportunities for research in
emerging countries in which Western experience can be
applied to local problems. The focus is to translate the re-
sults of clinical research into clinical practice on a global
basis, rather than only in those parts of the world where
data have been obtained.
Bolivia is a country in which a large percent of the pop-
ulation live at high altitude. This prompted us to begin our
research program with a pilot experiment targeting these
patients. The aim was to demonstrate that polycythemia
can be a risk factor for the development of protein-
uria, and that pharmacologic intervention may help con-
trol high-packed cell volume and reduce urinary protein
excretion, which eventually could translate to the preven-
tion of renal disease progression. Indeed, people accli-
matized to high altitudes have above-normal hemoglobin
levels to maintain oxygen delivery to tissues. This increase
is mainly mediated by expansion in erythrocyte mass sus-
tained by raised production of erythropoietin [30]. In the
early phase of acclimatization, erythropoietin production
is stimulated by decreased blood oxygen concentration
and consequent decreased oxygen delivery to the kid-
ney [31]. However, a raised hemoglobin concentration
inhibits production of erythropoietin. The final effect of
this negative feedback is a new equilibrium character-
ized by a normal blood oxygen concentration, increased
volume of erythrocytes and packed cell volume, and nor-
mal or slightly raised erythropoietin concentrations [32].
In about 15% of cases, however, this compensated sta-
tus is achieved at very high-packed cell volume levels
(>55%) that are frequently associated (about 40% of the
time) with persistent proteinuria and possibly with an in-
creased risk of cardiovascular complications. Inhibition
of the renin-agiotensin system by angiotensin-converting
enzyme (ACE) inhibitors or angiotensin II receptor an-
tagonists has proved effective for the treatment of an-
other form of secondary polycythemia that follows renal
transplant and is sustained by increased erythropoietin
activity [33].
Here, we aimed to investigate whether an ACE
inhibitor could be beneficial in altitude polycythemia, an-
other form of secondary erythropoietin-dependent poly-
cythemia. Our primary goal was the effect of enalapril
on packed cell volume, hemoglobin concentration, and
urinary protein excretion rate. Secondary goals were the
relations between packed cell volume and hemoglobin
concentration and urinary protein excretion rate at study
entry, and the relations between reduction in packed cell
volume or hemoglobin concentration and reduction in
urinary protein excretion rate during treatment.
This was a prospective randomized study in 26 pa-
tients of mixed Indian and European (mostly Spanish)
ethnic origin, born at altitudes of 3200 to 4000 m, who
had lived in La Paz (3600 m) for at least 1 year. Diagno-
sis of polycythemia and persistent proteinuria was made
respectively on the basis of packed cell volume ≥55%,
and urinary protein excretion rate ≥150 mg/24 h, mea-
sured on 2 or more occasions, 2 months apart, in other-
wise healthy people. Exclusion criteria considered were:
diastolic blood pressure >90 mm Hg, diabetes, chronic
pulmonary or cardiac disease, polycythemia vera, renal
insufficiency (serum creatinine >1.4 mg/dL), or an ultra-
sound suggestive of renal, renovascular, or urinary tract
disease. Patients with clinical or laboratory evidence of
urinary tract infection were assessed after completion of a
course of antibiotic treatment and a negative result from
urine culture. All participants gave informed oral con-
sent. Thirteen participants were assigned to the ACE in-
hibitor enalapril (5 mg/day) for 2 years (study group) and
13 patients to no treatment (controls). Treatment alloca-
tion was open to patients and doctors. All patients were
interviewed in person for treatment compliance and side
effects every 3 to 6 months for 2 years. Because of eco-
nomic constraints, laboratory assessments were repeated
at 12 and 24 months’ follow-up. Other antihypertensive
drugs, but not ACE inhibitors, were allowed for patients
who developed diastolic blood pressure of more than
90 mm Hg.
In all participants, baseline packed cell volume was sig-
nificantly and positively correlated with body weight (r =
0.46, P = 0.02) and systolic (r = 0.49, P < 0.01) and di-
astolic (r = 0.40, P < 0.04) blood pressure, and highly
correlated with serum creatinine (r = 0.61, P < 0.0009)
and urinary protein excretion rate (r = 0.56, P < 0.003).
Correlation with age was of borderline significance. Sys-
tolic and diastolic blood pressure decreased slightly in
study patients and increased (not significantly) in con-
trols. Packed cell volume, hemoglobin concentration, and
urinary protein excretion significantly decreased in pa-
tients treated with an ACE inhibitor, but in controls, the
packed cell volume and protein excretion rate increased.
At 12-month and 24-month follow-up, differences be-
tween the 2 groups in these 3 parameters were highly
significant (P < 0.01). In study patients, but not con-
trols, 12-month and 24-month changes in packed cell
volume were positively correlated with changes in sys-
tolic blood pressure and urinary protein excretion rate
(Table 2). Linear regression analysis performed per pa-
tient found a positive and highly significant correlation
between changes in packed cell volume and proteinuria
(r = 0.88, P < 0.0001) at 6, 12, 18, and 24 months as com-
pared with baseline.
In summary, our results showed that in patients with al-
titude polycythemia, long-term treatment with low doses
of enalapril safely prevented increase in arterial blood
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Table 2. Within-patient correlation between changes in packed cell
volume and other characteristics
Correlation coefficient (r) P value
Systolic BP 0.39 0.04
Diastolic BP 0.33 0.08
Protinuria 0.88 0.0001
pressure and progressively reduced packed cell volume
and proteinuria. Reductions in packed cell volume were
independent of changes in arterial blood pressure and
renal function and were positively correlated with re-
duction in proteinuria. The possibility exists that the de-
cline of both packed cell volume and proteinuria has
an additive effect in decreasing renal and cardiovascular
complications of altitude polycythemia and, in the long
term, should substantially reduce morbidity and mortal-
ity. Aside from its scientific value, this study can be taken
as an example of how, by rationalizing resources and in-
vesting in research programs, renal disease progression
and cardiovascular risk may eventually improve, which
ultimately should translate into better quality of life for
patients. By reducing the need for dialysis and thus pro-
viding alternatives to costly RRT, an overall benefit would
accrue to the national health system.
CONCLUSION
The data from Bolivia recall a rather obvious truth: for
an impressively large proportion of the world’s popula-
tion, a basic knowledge of their needs is not available.
The transformation of the Bolivian pilot model into a
systematic program applicable to most invisible emerg-
ing countries may be seen as a task of national nephrology
societies, with methodologic and economic support of in-
ternational bodies.
The Bolivian experience, however, also underlines that
education and training of health professionals is the first
priority. A comprehensive training program for physi-
cians and nurses should be established and carried out in
selected institutions in developed countries. The oppor-
tunity to train in different societies is a rich experience for
them. What is needed is an acknowledgment that insti-
tutions in developed countries have an ethical obligation
to facilitate the return of health professionals to their
own emerging countries. The plan is to impress upon the
health personnel, who will be providing first-line medi-
cal care in their countries, the need for early diagnosis
of kidney disease and the use of preventive measures
readily available in the country. Moreover, the aim of
these developments must be the establishment of sustain-
able research and development of partnerships between
the emerging and the developed world. Ultimately, this
would require building research infrastructures in emerg-
ing countries as reference centers for various prevention
programs. Academia in the developed world must estab-
lish lasting ties with its partners in the developing world,
which cannot survive another 10 years of neglect. How-
ever, implementation of such an ambitious program of
prevention of renal diseases can be realized only through
a coordinated approach among local health authorities,
national societies of nephrology, and International Soci-
ety of Nephrology-Commission for the Global Advance-
ment of Nephrology, and the involvement of interna-
tional agencies such as the World Health Organization
and the World Bank.
Reprint requests to Giuseppe Remuzzi, M.D., Mario Negri Institute
for Pharmacological Research, Via Gavazzeni 11, 24125 Bergamo, Italy.
E-mail: gremuzzi@marionegri.it
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